12 completed, 4 active not recruiting, 3 terminated, 1 withdrawn. 20 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 12, Active not recruiting 4, Terminated 3, Withdrawn 1 |
| Phase 2 | 5 | Active not recruiting 3, Completed 2 |
Follow Sham therapy: new trials by email Literature Review of Sham therapy trials Research Report on Sham therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care Haloperidol, Lorazepam, Placebo - Delirium, Locally Advanced Malignant Neoplasm | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 110 | 2019-07-17 | 2026-06-15 |
| Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer Exercise Intervention, Methylphenidate, Placebo - Prostate Carcinoma | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 200 | 2019-03-25 | 2026-11-04 |
| Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer Placebo, Questionnaire Administration, Ropivacaine Hydrochloride - Bladder Carcinoma, Post-operative Pain | Phase 3 | Withdrawn | University of Southern California | 2019-02-25 | 2019-04-16 | |
| Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Anamorelin Hydrochloride, Placebo, Questionnaire Administration - Anorexia, Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2018-11-27 | 2026-10-06 |
| A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy Laboratory Biomarker Analysis, Methylphenidate, Physical Activity - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 212 | 2018-08-02 | 2026-10-06 |
| Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride - Breast Carcinoma | Phase 3 | Completed | University of Rochester NCORP Research Base | 1363 | 2018-04-19 | 2025-09-25 |
| Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer Netupitant, Palonosetron, Palonosetron Hydrochloride - Malignant Neoplasm, Nausea | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 53 | 2017-05-03 | 2023-10-17 |
| Oxybutynin Chloride in Managing Hot Flashes Oxybutynin Chloride, Placebo, Quality-of-Life Assessment - Breast Carcinoma, Ductal Breast Carcinoma In Situ | Phase 3 | Completed | Academic and Community Cancer Research United | 150 | 2016-12-09 | 2020-01-18 |
| Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy Gabapentin, Placebo, Questionnaire Administration - Bladder Carcinoma | Phase 2 / Phase 3 | Completed | University of Washington | 25 | 2015-04-22 | 2019-06-04 |
| Laser for Oral Mucositis in Pediatric Onco-hematology Laser therapy, Sham therapy - Stomatitis | Phase 3 | Completed | IRCCS Burlo Garofolo | 101 | 2013-09-01 | 2016-05-04 |
| Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Carboplatin, Glutathione, Laboratory Biomarker Analysis - Chemotherapeutic Agent Toxicity, Neuropathy | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 195 | 2009-12-01 | 2017-02-23 |
| Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer Calcium Gluconate, Magnesium Sulfate, Placebo - Neuropathy, Pain | Phase 3 | Terminated | Mayo Clinic | 1 | 2009-11-01 | 2016-02-04 |
| Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Bevacizumab, Docetaxel, Filgrastim - Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 107 | 2009-11-01 | 2026-06-24 |
| Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy - Glioblastoma, Gliosarcoma | Phase 3 | Completed | National Cancer Institute (NCI) | 637 | 2009-04-15 | 2019-07-24 |
| Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment - Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 210 | 2008-06-15 | 2026-06-23 |
| Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Bevacizumab, Carboplatin, Paclitaxel - Breast Carcinoma, Recurrent Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 96 | 2007-11-01 | 2026-06-23 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment - Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 1943 | 2006-04-24 | 2026-06-23 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Mucosal Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 823 | 2005-06-01 | 2015-10-19 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery Laboratory Biomarker Analysis, Placebo, Sargramostim - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 815 | 2000-02-23 | 2026-06-24 |
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Fallopian Tube Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Pain (2) · Recurrence (2) · Urinary Bladder Neoplasms (2) · Anorexia (1) · Breast Carcinoma In Situ (1) · Brenner Tumor (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Renal Cell (1) · Delirium (1)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (5) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1) · IRCCS Burlo Garofolo (1) · Mayo Clinic (1) · University of Rochester NCORP Research Base (1) · University of Southern California (1) · University of Washington (1)
United States (19) · Canada (3) · Australia (1) · Brazil (1) · Israel (1) · Italy (1) · Japan (1) · Puerto Rico (1) · South Korea (1)
Charles Loprinzi (3) · David Hui (2) · Sriram Yennu (2) · David H Lawson (1) · Giulio Andrea Zanazzo, MD (1) · Ingrid Mayer (1) · Jonathan Wright (1) · Keith Flaherty (1) · Luke Peppone (1) · Mark A Socinski (1) · Mark Gilbert (1) · Martee Hensley (1) · Matteo Biasotto, DDS (1) · Naomi S Balzer-Haas (1) · Robert Burger (1)
PMID 21941283, PMID 22204724, PMID 23219660, PMID 23248256, PMID 24552317, PMID 25713428, PMID 26351350, PMID 26487588, PMID 26969090, PMID 28161554, PMID 28278333, PMID 28945839, PMID 29550184, PMID 31216226, PMID 31703971, PMID 33388382, PMID 34298376, PMID 34405965, PMID 34480522, PMID 35144591, PMID 36252167, PMID 37185961, PMID 37433436, PMID 38197040, PMID 38967884, PMID 40742738
U10CA021115 (3), P30CA015083 (2), U10CA027469 (2), U10CA180820 (2), U10CA180868 (2), P30CA014089 (1), P30CA015704 (1), R01CA200579 (1), U10CA021661 (1), U10CA023318 (1), U10CA031946 (1), U10CA037404 (1), U10CA180794 (1), U10CA180821 (1), UG1CA189961 (1)